(Q39353140)

11 September 2017

title

The crossregulation between ERK and PI3K signaling pathways determines the tumoricidal efficacy of MEK inhibitor (English)

1 reference

11 September 2017

6

Kwang-Hyun Cho

1 reference

11 September 2017

Jae-Kyung Won

1

1 reference

11 September 2017

Hee Won Yang

2

1 reference

11 September 2017

Sung-Young Shin

3

1 reference

11 September 2017

Jong Hoon Lee

4

1 reference

11 September 2017

Won Do Heo

5

1 reference

11 September 2017

publication date

4 May 2012

1 reference

Journal of Molecular Cell Biology

11 September 2017

published in

1 reference

11 September 2017

volume

4

1 reference

11 September 2017

issue

3

1 reference

11 September 2017

page(s)

153-163

1 reference

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS021

Systems-level interactions between insulin-EGF networks amplify mitogenic signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS021

BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS021

MEK1 mutations confer resistance to MEK and B-RAF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS021

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS021

Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS021

A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS021

Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS021

RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS021

Factors underlying sensitivity of cancers to small-molecule kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS021

A robustness-based approach to systems-oriented drug design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS021

Targeting the cancer kinome through polypharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS021

High-order combination effects and biological robustness

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS021

Cell signaling by receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS021

Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS021

The docking protein Gab1 is the primary mediator of EGF-stimulated activation of the PI-3K/Akt cell survival pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS021

Environment-mediated drug resistance: a major contributor to minimal residual disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS021

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS021

Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS021

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS021

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS021

Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS021

Systems-biology approaches for predicting genomic evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS021

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS021

Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS021

Phosphatidylinositol-3-OH kinase as a direct target of Ras

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS021

A hidden incoherent switch regulates RCAN1 in the calcineurin-NFAT signaling network.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS021

BRAF mutation predicts sensitivity to MEK inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS021

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS021

Activation of phosphoinositide 3-kinase gamma by Ras.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS021

Robustness against mutations in genetic networks of yeast.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS021

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS021

Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS021

Metabolic control analysis: biological applications and insights

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS021

Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS021

21 January 2018

Identifiers

DOI

10.1093/JMCB/MJS021

1 reference

11 September 2017

1 reference